Last reviewed · How we verify
NCT06946095
Efficacy and Safety of Xinyue Capsule in the Treatment of Heart Failure With Preserved Ejection Fraction
Phase 3 trial testing Chinese patent medicine in Heart Failure in 246 participants. Not yet recruiting.
31 October 2027
Quick facts
| Lead sponsor | Beijing Anzhen Hospital |
|---|---|
| Phase | Phase 3 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 246 |
| Start date | 20 May 2025 |
| Primary completion | 31 October 2027 |
| Estimated completion | 31 October 2027 |
Drugs / interventions tested
- Chinese patent medicine — full drug profile →
Conditions studied
- Heart Failure — all drugs for Heart Failure →
Sponsor
Beijing Anzhen Hospital
Who can join
18 and older, any sex, with Heart Failure. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to evaluate the effect of Xinyue Capsule in the improvement cardiac function and reduction the level of heart failure biomarker NT-proBNP in patients suffering from HF with an ejection fraction greater than or equal to 50%. Researchers will also collect information on how much the heart disease has impact on patient's lives, and how well Xinyue Capsule treatment is tolerated. The study plans to enroll 246 male and female patients of the age of 18 years and above suffering from heart failure with ejection fraction greater than or equal to 50%. Participants will take the study product as oral tablet with a dose 0.6 g Tid daily. Study duration will be up to 12 weeks.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06946095
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Chinese patent medicine
Trials testing the same drug.
- NCT05309343 — Cohort Study on Treatment of Cardiovascular Diseases With Traditional Chinese Medicine · recruiting
- NCT04026724 — Retrospective Clinical Study on Adjuvant Treatment of Coronary Heart Disease Angina Pectoris With Chinese Patent Medicin · unknown
- NCT04022031 — Clinical Study on Adjuvant Treatment of Coronary Heart Disease Angina Pectoris With Chinese Patent Medicine · unknown
Other recruiting trials for Heart Failure
Currently open trials in the same condition.
- NCT06118983 — Improving TRansitions ANd OutcomeS for Heart FailurE Patients in Home Health CaRe (I-TRANSFER-HF) · NA · recruiting
- NCT07496372 — Efficacy and Safety of Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Injection (HiCM-188) in Advanced Heart · Phase 3 · recruiting
- NCT07527156 — Prolonged Nasogastric Administration of Ketones in Decompensated Heart Failure · Phase 4 · recruiting
- NCT07263035 — Urine Sodium-Driven Diuretic Adjustment Strategy in Acute Decompensated Heart Failure · Phase 4 · recruiting
- NCT07531966 — Vascular Complications After Kidney Transplantation · recruiting
Other Beijing Anzhen Hospital trials
Trials by the same sponsor.
- NCT07521488 — LLM-Based Intelligent Health Management Assistant in Life-Cycle Health Management of Cardiac Surgery Patients · NA · not yet recruiting
- NCT07470814 — Multidisciplinary Collaborative Care System for Acute Myocardial Infarction Complicated With Cardiogenic Shock · not yet recruiting
- NCT07444372 — Start CPAP Therapy in Obstructive Sleep Apnea Patients After Atrial Fibrillation Ablation · NA · not yet recruiting
- NCT07256197 — PCSK9 Inhibitors in the Treatment of Calcific Aortic Stenosis · Phase 3 · not yet recruiting
- NCT07485101 — Glycemic Targets During CPB in Elderly Diabetes · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06946095 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Beijing Anzhen Hospital
- Last refreshed: 27 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06946095.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing